SERAPHIN study

SERAPHIN - STUDY WITH ENDOTHELIN RECEPTOR ANTAGONIST IN PULMONARY ARTERIAL HYPERTENSION TO IMPROVE CLINICAL OUTCOME. SERAPHIN (Study with an Endothelin Rece...

Hepatology

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyle...

Pain

Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in term...

Gynecology

Gynecology is the study of diseases affecting the reproductive organs of women and girls. Add the Gynecology News Channel to your RSS reader;

Viruses

A virus is a small infectious agent that can replicate only inside the living cells of organisms. Virus particles (known as virions) consist of two or three parts: the genetic material made from eit...

Desvenlafaxine acts against hot flashes: study

NEW YORK (Reuters Health) - The antidepressant desvenlafaxine (Pristiq, Pfizer) can reduce hot flashes in postmenopausal women, researchers said in a recent paper.

Desvenlafaxine safely curbs hot flushes

NEW YORK (Reuters Health) - Desvenlafaxine (Pristiq, Pfizer) maintains its efficacy in reducing menopausal vasomotor symptoms and does so safely, according to two reports online December 24 in...

Pfizer Announces Top-Line Efficacy Results From A Phase 4 Study Of Pristiq (desvenlafaxine) For The Treatment Of Major Depressive Disorder (MDD) In Adults

New Data Add to Evidence Supporting PRISTIQ as a Treatment Option for MDD NEW YORK--(BUSINESS WIRE)--Jan 24, 2013 - Pfizer Inc. (NYSE: PFE) announced today that a Phase 4 study evaluating the efficacy...

News and press releases: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 March 2013

The PRAC welcomed the appointment by the European Commission of one member and alternate each representing healthcare professionals and patient organisations.

News and press releases: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 January 2013

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) held its sixth meeting from 7 to 10 January 2013. At the meeting, the PRAC assessed available data related to safe...

Pharmacovigilance Risk Assessment Committee (PRAC) Present At SMi's 3rd Annual Event On Pharmacovigilance, London UK

In recent weeks, The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended restrictions in the use of strontium ranelate (Protelos/Osseor) to reduce...

Four new safety referrals evaluated as impact of new pharmacovigilance legislation kicks in, says EMA

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) held its fifth meeting November 26-29, 2012, at which the PRAC started a review of four medicines that are nationally...

Recommendation to suspend tetrazepam-containing medicines endorsed by CMDh

Following the recent recommendation by the Pharmacovigilance Risk Assessment Committee (PRAC), the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) has endorsed...

Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.

PURPOSE: To assess the effects of venlafaxine extended-release (XR) capsules and desvenlafaxine extended-release (XR) tablets upon indinavir pharmacokinetic properties when co-ad...

A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder.

BACKGROUND: In an effort to establish the lowest effective dose of desvenlafaxine (administered as desvenlafaxine succinate), we assessed the efficacy, safety, and tolerability of 10- and 50-mg/day de...

Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms.

Objective To assess effects of desvenlafaxine (administered as desvenlafaxine succinate) on secondary outcomes of mood, climacteric symptoms, and treatment satisfaction in postmenopausal women with mo...

Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.

Importance of the field: Genetic and pharmacologically-driven variations in common mechanisms involved in the disposition of antidepressant medications may contribute to variable interpatient response...

HAM-D17 and HAM-D6 Sensitivity to Change in Relation to Desvenlafaxine Dose and Baseline Depression Severity in Major Depressive Disorder.

INTRODUCTION: This retrospective analysis compared sensitivity to change on the 17-item and 6-item HAMILTON RATING SCALES FOR DEPRESSION (HAM-D (17) and HAM-D (6), respectively) in relation to antidep...